Roche wins earlier-than-expected approval for blockbuster Tecentriq in rare soft tissue cancer

Roche’s pharma chief Bill Anderson is taking a victory lap before he steps down at the end of the year.

The FDA last week approved Roche’s blockbuster PD-L1 drug Tecentriq for adults and kids suffering an extremely rare soft tissue cancer, three weeks ahead of the initial goal date.


Click to view original post